Ancillary Functional Studies for the CCTRN

CCTRN 的辅助功能研究

• 批准号: 7689238
• 负责人: Carl J Pepine
• 金额: $ 36.72万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7689238
• 关键词: Acute; Address; Adhesions; Ancillary Study; Autologous; Biological Assay; Blood Cells; Blood Tests; Bone Marrow; Cardiac; Cardiovascular Diseases; Cardiovascular system; Cell Therapy; Cell Transplants; Cell physiology; Cells; Characteristics; Chronic; Clinical; Clinical Treatment; Clinical Trials Network; Coronary Arteriosclerosis; Dose; Endothelial Cells; Enrollment; Functional disorder; Future; Heart; Heart Diseases; Hematopoietic; Impairment; Individual; Infarction; Injection of therapeutic agent; Institutes; Laboratories; Laboratory Study; Marrow; Measures; Mediating; Modeling; Myocardial; National Heart, Lung, and Blood Institute; Natural regeneration; Nitric Oxide; Outcome; Patients; Peripheral Blood Mononuclear Cell; Phase; Physiological; Property; Reality Therapy; Reporting; Rheology; Risk; Role; Sample Size; Sampling; Screening procedure; Source; Stem cells; Testing; Therapeutic; Therapeutic Intervention; Therapeutic Studies; Therapy Clinical Trials; Time; Tissues; Transplantation; abstracting; angiogenesis; base; cell motility; conventional therapy; implantation; improved; indexing; insight; interest; method development; migration; minimal risk; neovascularization; novel; patient safety; repaired; response; stem; success; trafficking

DESCRIPTION (provided by applicant): The NHLBI recently instituted the Cardiovascular Cell Therapy Research Network (CCTRN) to conduct novel cell therapy clinical trials for the treatment of cardiovascular diseases. We seek to bridge the gap between cells injected and clinical outcome, and will test the overarching hypothesis that functional characteristics of injected cells dictate patients' responses to marrow cell therapy injections. We propose to measure cell function before cell therapy injections, enabling us to quantify relationships between cell function results and subsequent clinical outcomes. Specifically, we aim to test cell migration and nitric oxide activity based on the proven utility of these mechanisms in predicting myocardial neovasculogenesis. Whereas the source of transplanted cells are the same (bone marrow) for all three CCTRN trials (FOCUS, TIME and Late TIME), the clinical response measures of interest for this proposal are the primary clinical outcomes of the respective trial. The ability to predict outcome of a cell therapeutic intervention based on functional characteristics of the injected cells will greatly accelerate development of methods to improve cell function and the pace of cell therapy. The NHLBI recently instituted the Cardiovascular Cell Therapy Research Network (CCTRN) to conduct novel cell therapy clinical trials for the treatment of cardiovascular diseases. This proposal establishes a CCTRN ancillary functional studies laboratory consortium to bridge the gap between cells injected and clinical outcome. Results from ancillary studies in this proposal are crucially important for the interpretation of current CCTRN trials and will be used to construct future CCTRN cell therapy trials. (End of Abstract)

描述（由申请人提供）： NHLBI最近建立了心血管细胞疗法研究网络（CCTRN），以进行新的细胞疗法临床试验，以治疗心血管疾病。我们试图弥合注射细胞和临床结果之间的差距，并将检验总体假设，即注射细胞的功能特征决定了患者对骨髓细胞疗法注射的反应。我们建议在注射细胞治疗之前测量细胞功能，使我们能够量化细胞功能结果与随后的临床结果之间的关系。具体而言，我们旨在基于这些机制在预测心肌新生血管生成方面的证明效用来测试细胞迁移和一氧化氮活性。对于所有三项CCTRN试验（焦点，时间和晚期），移植细胞的来源是相同的（骨髓），但该提案的临床响应度量是相应试验的主要临床结果。根据注射细胞的功能特征来预测细胞治疗干预的结果的能力将极大地加速改善细胞功能和细胞疗法速度的方法。 NHLBI最近建立了心血管细胞疗法研究网络（CCTRN），以进行新的细胞疗法临床试验，以治疗心血管疾病。该提案建立了一个CCTRN辅助功能研究实验室联盟，以弥合注射细胞和临床结果之间的差距。该提案中辅助研究的结果对于解释当前的CCTRN试验至关重要，将用于构建未来的CCTRN细胞疗法试验。 （抽象的结尾）